Characteristics | Primary RP, n = 18 | SSc, n = 25 | p |
---|---|---|---|
Age, yrs | 51.7 (19.3) | 59.2 (19.8) | 0.03 |
Age at RP onset, yrs | 20 (24) | 35 (19) | 0.02 |
Age at diagnosis, yrs | 43 (6) | 45 (19) | 0.61 |
Male, n (%) | 4 (22.2) | 5 (20) | 1.00 |
Female, n (%) | 14 (77.8) | 20 (80) | 1.00 |
Vasodilatory therapy | |||
Any, n (%) | 5 (27.8) | 12 (48) | 0.22 |
Calcium antagonist | 3 (16.7) | 6 (24) | 0.71 |
ACEi | 0 (0) | 7 (28) | 0.03 |
SSRI | 2 (11.1) | 1 (4) | 0.56 |
ERA | 0 (0) | 2 (8) | 0.50 |
Smoking history, n (%) | |||
Never | 10 (55.6) | 13 (52) | 1.00 |
Ex | 7 (38.9) | 9 (36) | 1.00 |
Current | 1 (5.5) | 3 (12) | 0.63 |
Season enrolled, n (%) | |||
Autumn/winter | 10 (55.6) | 13 (52) | 1.00 |
Spring/summer | 8 (44.4) | 12 (48) | 1.00 |
Significant data are in bold face. IQR: interquartile range; RP: Raynaud phenomenon; SSc: systemic sclerosis; ACEi: angiotensin-converting enzyme inhibitor; SSRI: selective serotonin reuptake inhibitors; ERA: enthesitis-related arthritis.